Back to Careers
CEO and co-Founder Dr. Hanadie Yousef recognized as In Vivo’s 2024 Rising Leaders, which includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Back to Careers
Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.
Back to Careers
CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit
Back to Careers
Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leaders
Back to Careers
Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wasting
Back to Careers
Juvena gets FDA Orphan Drug nod for muscle regeneration therapy
Back to Careers
Juvena’s JUV-161 named FDA orphan drug for DM1
Back to Careers
Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1
Back to Careers
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
Back to Careers
Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”
